Overview
Proacta is a leader in bioinformatics and artificial intelligence-based medicine, providing advanced predictive models and data analysis tailored to the healthcare sector. The company specializes in revolutionary medical technologies that enhance the quality and efficiency of healthcare, as well as dedicated software solutions that support clinical decision-making and patient data management. Proacta also focuses on optimizing medical processes and personalizing therapies through the use of AI and machine learning.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 1.58
- High
- PLN 1.58
- Low
- PLN 1.56
- Volume
- 7.77K
- Avg. vol.
- 3.92K
- Market cap
- PLN 184.36M
- P/E ratio
- 157.00
- EPS
- PLN 0.01
- Shares outstanding
- 117.43M
- 52-week
- PLN 1.45 – 1.64
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLBTEVL00019
- Exchange
- NewConnect
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 551.32k | USD -105.89k | USD -44.84k |
| Q1 2026 | USD 1.67m | USD 492.17k | USD 488.38k |
| Q4 2025 | USD 925.41k | USD -130.09k | USD -159.47k |
| Q3 2025 | USD 1.19m | USD 377.45k | USD 359.37k |
Results for Q3 2026:Nov 16, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
PROACTA STRENGTHENS STRATEGIC COMPETENCIES
Proacta S.A. appoints Medical Advisory Board supporting development of certified medical products
Proacta SA signs letter of intent with VeritaMed – step towards commercialization of the “Dbam o Siebie” platform
Artificial intelligence in the fight against cervical cancer – Proacta team publication in a prestigious scientific journal
Estimated revenues of Proacta SA for Q1 2026
Proacta begins commercialization of the DBCU platform
Industry
Bank accounts
Registered as a VAT taxpayer on 2015-08-21. Active
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jun 13, 2024 | Commercial Companies Code notice |
Public aid
8 public aid cases recorded, with a total value of $1,016,982.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 16, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $3,025 | Prezes Banku Gospodarstwa Krajowego | |
| May 22, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $3,899 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Apr 22, 2025 | Aid for research and development projects: industrial research | $609,800 | Prezes Agencji Badań Medycznych |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
Making declarations of will on behalf of the company requires the joint action of two members of the management board or one member of the management board jointly with a commercial proxy.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Proacta.
Subsidiaries
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Momentumsp. z o.o. | $6,437,352.90 | themomentum.ai | |
| Addeptosp. z o.o. | $5,333,694.00 | addepto.com | |
| Radpointsp. z o.o. | $4,651,079.57 | radpoint.pl | |
| Digital Workforcesp. z o.o. | $3,978,442.66 | digitalworkforce.pl | |
| Instinctools Plsp. z o.o. | $3,509,787.64 | instinctools.com | |
| Apzumisp. z o.o. + limited partnership | $3,507,188.76 | apzumi.com | |
| Dac.Nextsp. z o.o. | $2,715,267.87 | dac.digital | |
| Prosomasp. z o.o. | $2,167,944.15 | prosoma.com | |
| Data4cure Polandsp. z o.o. | $1,824,382.17 | data4cure.com | |
| Upside Labsp. z o.o. | $1,468,774.96 | upsidelab.io |
Change history
| Date | Event |
|---|---|
| 2025-07-18 | PKD change (Removed: 62.01.Z, 62.02.Z, 62.03.Z, 62.09.Z, 63.12.Z, 73.12.C, 73.12.D; Added: 60.39.Z, 62.10.B, 62.20.B, 62.90.Z, 63.10.A, 72.10.Z, 73.12.Z) |
| 2024-09-12 | Share capital change (56,687,947.00 PLN → 58,712,516.50 PLN) |
| 2024-02-19 | Share capital change (55,147,947.00 PLN → 56,687,947.00 PLN) |
| 2023-09-21 | Share capital change (3,935,665.00 PLN → 55,147,947.00 PLN) |
| 2023-07-28 | Address change (Ul. Wierzbięcice 44a/40a, 61-568, Poznań → Ul. Srebrna 16, 00-810, Warszawa) |
FAQ
Last updated: 2026-07-11